Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBIT Margin (2022 - 2025)

Historic EBIT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 158.56%.

  • bioAffinity Technologies' EBIT Margin fell 745800.0% to 158.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 153.2%, marking a year-over-year decrease of 640700.0%. This contributed to the annual value of 95.64% for FY2024, which is 2192000.0% up from last year.
  • Per bioAffinity Technologies' latest filing, its EBIT Margin stood at 158.56% for Q3 2025, which was down 745800.0% from 198.16% recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' EBIT Margin registered a high of 80.84% during Q1 2024, and its lowest value of 169160.69% during Q1 2023.
  • Over the past 4 years, bioAffinity Technologies' median EBIT Margin value was 178.36% (recorded in 2025), while the average stood at 27600.56%.
  • As far as peak fluctuations go, bioAffinity Technologies' EBIT Margin surged by 1690798600bps in 2024, and later crashed by -1110800bps in 2025.
  • Over the past 4 years, bioAffinity Technologies' EBIT Margin (Quarter) stood at 69213.17% in 2022, then soared by 100bps to 105.83% in 2023, then dropped by -26bps to 133.47% in 2024, then fell by -19bps to 158.56% in 2025.
  • Its EBIT Margin stands at 158.56% for Q3 2025, versus 198.16% for Q2 2025 and 141.73% for Q1 2025.